Quantcast
Last updated on April 24, 2014 at 11:16 EDT

Latest cytarabine Stories

2013-12-16 08:25:29

- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute...

2013-12-10 08:29:38

- BL-8040 is currently in midst of Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014 - JERUSALEM, Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the...

2013-12-10 04:22:24

-- Interim Results of Tosedostat in Combination with Chemotherapy or Hypomethylating Agents in First-line Demonstrate 54 Percent Complete Response Rate and 12-Month Median Survival -- SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid...

2013-11-19 23:04:55

Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017. London (PRWEB) November 19, 2013 OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 Summary Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a...

2013-09-17 08:30:43

RIDGEFIELD, Conn., Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy. "This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the...

2013-05-23 12:26:45

WASHINGTON, May 23, 2013 /PRNewswire-USNewswire/ -- Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid leukemia (AML), the second most common form of leukemia in...

2012-12-10 16:39:14

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments. George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9. AML causes certain white blood cells to stop maturing, resulting in their uncontrolled...

2012-12-10 12:24:49

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy. In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free survival (EFS)...

2012-11-29 12:28:45

RIDGEFIELD, Conn., Nov. 29, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54(th) American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. Data include results from the Phase II portion of a Phase I/II study evaluating volasertib administered in addition to low-dose cytarabine (LDAC) compared to LDAC monotherapy...

2012-08-16 10:50:22

A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis (LCH) in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow. In the study, appearing in the current issue of PLOS ONE, researchers reviewed health records for 58 adults with the disease and compared the effectiveness of three chemotherapy treatments —...